Biogen Reports Phase 3 AFFIRM Results for Tysabri in Relapsing Multiple Sclerosis

Biogen today announced results from the Phase 3 AFFIRM trial evaluating Tysabri (natalizumab) in patients with relapsing multiple sclerosis. The trial met its primary endpoints, demonstrating significant reductions in annualized relapse rates and disability progression with Tysabri compared to placebo. These results led to FDA approval of Tysabri for relapsing MS.